Soluble CD40 Ligand Levels in Otherwise Healthy Subjects With Impaired Fasting Glucose

Tasci, Ilker; Dogru, Teoman; Sonmez, Alper; Genc, Halil; Kilic, Selim; Olgun, Abdullah; Gok, Mahmut; Erdem, Gokhan; Erikci, Selahattin

doi:https://doi.org/10.1155/MI/2006/32508

Mediators of Inflammation

On this page

Abstract References Copyright Related Articles

Research Communication | Open Access

Volume 2006 | Article ID 032508 | https://doi.org/10.1155/MI/2006/32508

Soluble CD40 Ligand Levels in Otherwise Healthy Subjects With Impaired Fasting Glucose

Ilker Tasci,¹Teoman Dogru,¹Alper Sonmez,¹Halil Genc,¹Selim Kilic,²Abdullah Olgun,³Mahmut Gok,¹Gokhan Erdem,¹and Selahattin Erikci¹

Received01 Jun 2006

Accepted07 Aug 2006

Published03 Oct 2006

Abstract

Unlike diabetes mellitus and impaired glucose tolerance, it is not clear whether the subjects with impaired fasting glucose (IFG) are at increased risk of atherosclerosis and cardiovascular diseases. The CD40-CD40 ligand interaction is involved in the mechanism of atherosclerosis. We investigated whether soluble CD40L (sCD40L) as well as high sensitive C-reactive protein (hsCRP) levels are increased in subjects with IFG having no confounding factors for inflammation or atherosclerosis. Twenty four IFG subjects with no additional disorders and 40 appropriate healthy controls were studied. sCD40L and hsCRP levels in the IFG and control groups were similar. Blood pressures, total and LDL-cholesterol, and triglyceride levels were also similar, whereas HDL-cholesterol was lower and HOMA-IR indexes were higher in the IFG group. Though the sample size was small, the present data show that sCD40L seems not to alter in subjects with IFG suggesting that it might not be an independent risk factor for atherosclerosis.

References

D W Laight, M J Carrier, and E E Anggard, “Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy,” Diabetes/Metabolism Research and Reviews, vol. 15, no. 4, pp. 274–282, 1999.
View at: Publisher Site | Google Scholar
American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 27, no. suppl 1, pp. S5–S10, 2004.
View at: Google Scholar
J E Shaw, P Z Zimmet, A M Hodge et al., “Impaired fasting glucose: how low should it go?” Diabetes Care, vol. 23, no. 1, pp. 34–39, 2000.
View at: Google Scholar
M Hanefeld and T Temelkova-Kurktschiev, “The postprandial state and the risk of atherosclerosis,” Diabetic Medicine, vol. 14, no. suppl 3, pp. S6–S11, 1997.
View at: Publisher Site | Google Scholar
S H Saydah, M Miret, J Sung, C Varas, D Gause, and F L Brancati, “Postchallenge hyperglycemia and mortality in a national sample of U.S. adults,” Diabetes Care, vol. 24, no. 8, pp. 1397–1402, 2001.
View at: Google Scholar
S M Haffner, “Pre-diabetes, insulin resistance, inflammation and CVD risk,” Diabetes Research and Clinical Practice, vol. 61, no. suppl 1, pp. S9–S18, 2003.
View at: Publisher Site | Google Scholar
M Tominaga, H Eguchi, H Manaka, K Igarashi, T Kato, and A Sekikawa, “Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study,” Diabetes Care, vol. 22, no. 6, pp. 920–924, 1999.
View at: Google Scholar
U Schönbeck and P Libby, “The CD40/CD154 receptor/ligand dyad,” Cellular and Molecular Life Sciences, vol. 58, no. 1, pp. 4–43, 2001.
View at: Google Scholar
P Aukrust, F Müller, T Ueland et al., “Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes,” Circulation, vol. 100, no. 6, pp. 614–620, 1999.
View at: Google Scholar
A G Semb, S Van Wissen, T Ueland et al., “Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy,” Journal of the American College of Cardiology, vol. 41, no. 2, pp. 275–279, 2003.
View at: Publisher Site | Google Scholar
K Gokulakrishnan, R Deepa, V Mohan, and M D Gross, “Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome—the Chennai Urban Rural Epidemiology Study,” Metabolism: Clinical and Experimental, vol. 55, no. 2, pp. 237–242, 2006.
View at: Publisher Site | Google Scholar
D R Matthews, J P Hosker, A S Rudenski, B A Naylor, D F Treacher, and R C Turner, “Homeostasis model assessment: insulin resistance and $β$ -cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985.
View at: Publisher Site | Google Scholar
A Wasunna, A Whitelaw, R Gallimore, P N Hawkins, and M B Pepys, “C-reactive protein and bacterial infection in preterm infants,” European Journal of Pediatrics, vol. 149, no. 6, pp. 424–427, 1990.
View at: Publisher Site | Google Scholar
R W Simpson, J E Shaw, and P Z Zimmet, “The prevention of type 2 diabetes—lifestyle change or pharmacotherapy? A challenge for the 21st century,” Diabetes Research and Clinical Practice, vol. 59, no. 3, pp. 165–180, 2003.
View at: Publisher Site | Google Scholar
E A Ashley, V Raxwal, M Finlay, and V Froelicher, “Diagnosing coronary artery disease in diabetic patients,” Diabetes/Metabolism Research and Reviews, vol. 18, no. 3, pp. 201–208, 2002.
View at: Publisher Site | Google Scholar
DECODE Study Group and the European Diabetes Epidemiology Group, “Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria,” Archives of Internal Medicine, vol. 161, no. 3, pp. 397–405, 2001.
View at: Publisher Site | Google Scholar
P Mohanty, W Hamouda, R Garg, A Aljada, H Ghanim, and P Dandona, “Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 8, pp. 2970–2973, 2000.
View at: Publisher Site | Google Scholar
A J Jenkins, J D Best, R L Klein, and T J Lyons, “Lipoproteins, glycoxidation and diabetic angiopathy,” Diabetes/Metabolism Research and Reviews, vol. 20, no. 5, pp. 349–368, 2004.
View at: Publisher Site | Google Scholar
G Basta, A M Schmidt, and R De Caterina, “Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes,” Cardiovascular Research, vol. 63, no. 4, pp. 582–592, 2004.
View at: Publisher Site | Google Scholar
K Esposito, F Nappo, R Marfella et al., “Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress,” Circulation, vol. 106, no. 16, pp. 2067–2072, 2002.
View at: Publisher Site | Google Scholar
O A Mojiminiyi, N Abdella, M A Moussa, A O Akanji, H Al Mohammedi, and M Zaki, “Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 58, no. 1, pp. 37–44, 2002.
View at: Publisher Site | Google Scholar
A Ceriello, C Taboga, L Tonutti et al., “Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment,” Circulation, vol. 106, no. 10, pp. 1211–1218, 2002.
View at: Publisher Site | Google Scholar
M Hanefeld, C Koehler, E Henkel, K Fuecker, F Schaper, and T Temelkova-Kurktschiev, “Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes,” Diabetic Medicine, vol. 17, no. 12, pp. 835–840, 2000.
View at: Publisher Site | Google Scholar
D W Laight, M J Carrier, and E E Anggard, “Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy,” Diabetes/Metabolism Research and Reviews, vol. 15, no. 4, pp. 274–282, 1999.
View at: Publisher Site | Google Scholar
P E Szmitko, C-H Wang, R D Weisel, J R De Almeida, T J Anderson, and S Verma, “New markers of inflammation and endothelial cell activation. Part I,” Circulation, vol. 108, no. 16, pp. 1917–1923, 2003.
View at: Publisher Site | Google Scholar
R P Phipps, “Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 13, pp. 6930–6932, 2000.
View at: Publisher Site | Google Scholar
F Cipollone, C Ferri, G Desideri et al., “Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty,” Circulation, vol. 108, no. 22, pp. 2776–2782, 2003.
View at: Publisher Site | Google Scholar
Y Nishi, M Fukushima, H Suzuki et al., “Insulin secretion and insulin sensitivity in Japanese subjects with impaired fasting glucose and isolated fasting hyperglycemia,” Diabetes Research and Clinical Practice, vol. 70, no. 1, pp. 46–52, 2005.
View at: Publisher Site | Google Scholar
L-K Chen, M-H Lin, Z-J Chen, S-J Hwang, S-T Tsai, and S-T Chiou, “Metabolic characteristics and insulin resistance of impaired fasting glucose among the middle-aged and elderly Taiwanese,” Diabetes Research and Clinical Practice, vol. 71, no. 2, pp. 170–176, 2006.
View at: Publisher Site | Google Scholar
E Cersosimo and R A DeFronzo, “Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases,” Diabetes/Metabolism Research and Reviews. In press.
View at: Google Scholar
J S Yudkin, C DA Stehouwer, J J Emeis, and S W Coppack, “C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 4, pp. 972–978, 1999.
View at: Google Scholar
E S Kang, H J Kim, C W Ahn et al., “Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 69, no. 2, pp. 151–159, 2005.
View at: Publisher Site | Google Scholar
C Snehalatha, V Vijay, R Suresh Mohan et al., “Lack of association of insulin resistance and carotid intimal medial thickness in non-diabetic Asian Indian subjects,” Diabetes/Metabolism Research and Reviews, vol. 17, no. 6, pp. 444–447, 2001.
View at: Publisher Site | Google Scholar
E Bonora, R Tessari, R Micciolo et al., “Intimal-medial thickness of the carotid artery in nondiabetic and NIDDM patients: relationship with insulin resistance,” Diabetes Care, vol. 20, no. 4, pp. 627–631, 1997.
View at: Google Scholar
Y Igarashi, T Mita, R Mizuno et al., “Characteristics of Japanese subjects who progress from normal to impaired glucose tolerance. Longitudinal study excluding changes in body weight,” Endocrine Journal, vol. 52, no. 6, pp. 683–689, 2005.
View at: Publisher Site | Google Scholar
D J Rader, K Ikewaki, N Duverger et al., “Very low high-density lipoproteins without coronary atherosclerosis,” Lancet, vol. 342, no. 8885, pp. 1455–1458, 1993.
View at: Publisher Site | Google Scholar
R P Tracy, B M Psaty, E Macy et al., “Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 10, pp. 2167–2176, 1997.
View at: Google Scholar
P Greenland, M D Knoll, J Stamler et al., “Major risk factors as antecedents of fatal and nonfatal coronary heart disease events,” Journal of the American Medical Association, vol. 290, no. 7, pp. 891–897, 2003.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2006 Ilker Tasci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

258

Downloads

927

Citations